An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer.
Joan JacobLiezl E FranciscoTreena ChatterjeeZhengdong LiangShraddha SubramanianQingyun J LiuJulie H RoweKendra S CarmonPublished in: British journal of cancer (2023)
This study provides the rationale for the future development of a GPR56-targeted ADC approach to potentially treat a large fraction of MSS CRC patients.
Keyphrases
- cancer therapy
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- fatty acid
- clinical trial
- prognostic factors
- peritoneal dialysis
- stem cells
- magnetic resonance
- magnetic resonance imaging
- mesenchymal stem cells
- patient reported outcomes
- computed tomography
- bone marrow
- cell therapy
- diffusion weighted imaging
- diffusion weighted